SciSight Ecosystem
WoS SCIE Q1CAS 4区Subscription

Molecular and Cellular Oncology

Country: United Kingdom•WoS SCIE Quartile: Q1•Identifier (ISSN):2372-3556(Print)•Articles / Year: 4
Clarivate JCR Index Advisory: Not Indexed in Latest JCR
Clarivate Impact Factor (IF 2024)Q1
N/A

Leading citation impact metric from Clarivate Journal Citation Reports

H-Index (Hirsch Index)
N/A

papers with at least that number of citations each

WoS: SCIE / JCRQ1
Self-Citation RateN/A
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessSubscription
4articles/year
0% Gold OA•72.73% Original Research

State Council for Professorship (HĐGSNN) Scoring

Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)

1.00pts
Latest Max Score
Estimated (Dec 26)
Scoring Basis: WoS Q4

HĐGSNN Score History

By article publication year
YearMax ScoreEvaluation DetailsSource
20251.00đ
WoS Q4(IF: 1.9)
🔵 Computed
20231.00đ
WoS Q4(IF: 2.1)
🔵 Computed

Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.

Aims & Scope

For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.

Topics Covered (Recognized by AI)
Biology99.9%Genetics99%Chemistry94.6%Biochemistry94.1%Medicine88.3%Internal medicine80.7%Gene77.8%Cell biology73.9%Cancer research62.4%Cancer61.8%Apoptosis38.8%Physics32.3%Organic chemistry26.7%Signal transduction23.9%Nuclear magnetic resonance23.6%Cell23.6%DNA23.2%Immunology23%Enzyme22.4%Pathology21.2%

SCImago & Scopus Journal Intelligence

Not indexed in SCImago / Scopus database

This journal is currently not indexed in Scopus or is an academic publication indexed exclusively in Web of Science (WoS).

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
4区 (Zone 4)Medicine
Minor Category (Specific Field):
4区ONCOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Publisher Review Speed
Updating
Average time to first editorial decision
Online Publication Speed
Updating
Time from acceptance to online publication
Official Acceptance Rate
Updating
Manuscript acceptance rate confirmed by the publisher
Open Access Model
Subscription
OA publishing option or traditional subscription
Publisher
Taylor & Francis
Publication Language
English
Frequency
Periodic
Indexing & Databases
ScopusPubMed

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR

No WoS category details available for this journal.

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
YearImpact FactorArticles / YearTotal Citations
2026—40
20251.91113
2024—1146
20232.1424
2022—18106
2021—91416
2020—122933
2019—86742
2018—94983
2017—1071,097
2016—1121,078
2015—2564,859
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Impact Factor Trend (2018–2024)

Clarivate IF trend for Molecular and Cellular Oncology

WoS Q1
1223202320251.90
Annual Impact Factor Metric
2025:1.9

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: N/A

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: a73e5f8f-9621-415a-bfdd-d9a2a254e4f1
Database Updated: 2026-10-01